N/A N=42 A Randomized Cross Over Trial of Two Treatments for Sleep Apnea in Veterans With Post-Traumatic Stress Disorder
Obstructive Sleep Apnea
Primary: Residual Apnea Hypopnea Index — 3.9; 26.3 events per hour — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=46 A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins
Hypercholesterolemia · Dyslipidemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 85 — 4.05; -14.95; -44.84 percent change — p=0.0137
Phase 3 N=943 Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 95.2; 98.2 percentage of participants
Phase 2 N=109 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
Tardive Dyskinesia
Primary: Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6 — -2.5; -3.3 units on a scale — p=0.2966
Phase 4 N=65 Simplified Insulin Protocol Using Lantus in Elderly
Diabetes
Primary: Change in Duration of Hypoglycemia Episodes — 277; 111; 97 minutes of hypoglycemia
Phase 2 N=19 Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain
Small Cell Lung Carcinoma
Primary: Safety of Lithium Carbonate as Measured by Number of Patients in the Safety lead-in Who Experienced a Dose-limiting Toxicity (DLT) — 1 Participants
N/A N=1,578 Online Social Networking for HIV Prevention
HIV
Primary: Proportion of Condom Usage — .68; .56 proportion of condom use
Phase 2 N=25 Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma
Advanced · Metastatic · Soft Tissue Sarcoma
Primary: 6-month Progression-free Survival Rate (PFS) — 12 participants
Phase 2 N=100 Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy
Prostate Cancer
Primary: Number of Patients With Late Treatment-related Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) — 12 Participants
N/A N=25 Combined Use of Er:YAG and Nd:YAG Laser
Chronic Periodontitis
Primary: Clinical Attachment Level Change for Moderately Deep Pockets (4 mm≤PD≤6 mm) — 2.07; 2.12; 2.06; 2.09 mm
Phase 3 N=93 An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)
Osteoarthritis of the Knee
Primary: Percentage of Participants With Drug Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs) — 51.6; 7.5 Percentage of participants
Phase 4 N=34 Glargine Versus NPH in Patients With Chronic Kidney Disease
Type 2 Diabetes Mellitus · Chronic Kidney Disease
Primary: Difference in A1c Levels — 8.86; 8.21; 7.95; 8.44 percentage — p=0.00045
N/A N=120 Adolescent Trauma Recovery and Stress Disorders Collaborative Care (ATRSCC) Model Program Trial
Post-traumatic Stress Disorder · Alcohol Abuse · Alcohol Dependence
Primary: Number of Patients With High Levels of Adolescent PTSD Symptoms — 9; 12; 11; 12 Participants — p=0.71
Phase 2 N=30 Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients
Atrial Fibrillation · Coronary Artery Disease
Primary: Sensitivity of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD) — 80 Percentage of true positive cases
Phase 2 N=99 Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR) (Phase II) — 0; 5; 14 Participants